Broncatox

Levodropropizine

Method of action: Antitussive, Cough And Cold Preparations

Treatment option: Bronchitis, Influenza, Cough, Laryngitis, Pharyngitis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Broncatox

What is Broncatox?

Broncatox is a pharmaceutical intervention primarily utilized in the management of specific respiratory conditions characterized by chronic inflammation and mucus overproduction. It belongs to a class of medications designed to modulate the underlying biological pathways that contribute to airway narrowing and respiratory distress.

Mechanism of Action

The therapeutic effect of Broncatox is achieved through its interaction with targeted receptors in the pulmonary system. By influencing these pathways, the medication helps to:

Reduce Inflammation: It assists in decreasing the inflammatory response within the bronchial tissues, which can help minimize swelling and irritation in the airways.
Improve Airway Patency: By addressing the factors that cause bronchial constriction, it supports more consistent airflow to the lungs.
Mucus Regulation: It plays a role in managing the viscosity and volume of secretions, making it easier for the respiratory system to maintain clear passages.

Therapeutic Intent

Broncatox is typically prescribed as a maintenance therapy rather than a rescue treatment. Its objective is to provide long-term stabilization of lung function and to reduce the frequency and severity of symptomatic episodes. It is often used for patients who require ongoing pharmacological support to manage persistent respiratory challenges and to improve overall quality of life through better respiratory control.

What side effects are possible with Broncatox?

Possible Side Effects and Safety Information

The safety profile for Levodropropizine (Broncatox) is established by regulatory documents, which classify adverse reactions primarily by frequency and the organ system affected. The majority of documented side effects are categorized as Very Rare (occurring in less than 1 in 10,000 individuals) or Not Known (frequency cannot be determined from available data).

Documented Adverse Reactions

The most commonly noted adverse reactions involve the Nervous System (such as somnolence, headache, and dizziness) and the Gastrointestinal System (including nausea, vomiting, and abdominal pain). Reactions affecting the Skin and Subcutaneous Tissue (e.g., urticaria, rash, itching) are also documented.

Serious Safety Events

Regulatory reports include rare but serious adverse reactions, such as severe Anaphylactoid Reactions, reports of Convulsions (seizures), and specific cases of severe skin conditions like Epidermolysis or metabolic events like Hypoglycaemic Coma.

Population-Specific Restrictions

Use of Levodropropizine is subject to several explicit contraindications stated in official labeling. The medication is contraindicated in children under two years of age, and its use is strictly prohibited during pregnancy and lactation. Furthermore, caution is required in patients with severe renal insufficiency or severe hepatic disorders. It is also restricted for use in conditions characterized by excessive bronchial mucus discharge or impaired mucociliary function.

Safety Considerations

The potential for drowsiness means that caution is necessary when performing tasks requiring mental alertness, such as driving or operating machinery. Additionally, regulatory documents note the potential for additive sedative effects when used with other sedating agents.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory documents describing Levodropropizine (Broncatox) overdose emphasize the recognition of specific clinical signs and the implementation of essential supportive care. The principal documented manifestation expected after an overdose is a temporary transitional tachycardia. While high-dose exposures have been reported, including one instance in a young child that presented with non-severe abdominal pain and vomiting, no significant adverse effects have been observed after single doses up to 240 mg.

Mandatory Emergency Action

Immediate medical attention is required when evident clinical signs of overdose are present. The official regulatory mandate is to immediately initiate symptomatic and supportive therapies. Due to the statement that no specific antidote is known for Levodropropizine, management protocols described in the labeling often include the use of gastric lavage and activated charcoal as standard emergency measures when clinically appropriate.

Specialized Monitoring

Following an overdose, official documentation directs management teams to pay special attention to the monitoring of key physiological functions. This includes continuous observation of the patient's cardiac function, respiratory function, renal function, hepatic function, and careful tracking of fluid and electrolytic balance. This intensive monitoring requirement highlights why professional medical care must be sought immediately.

Therapeutic Uses of Broncatox

What Broncatox Treats: Main Uses and Benefits

Broncatox provides targeted symptomatic relief as an antitussive, applied in contexts where additional symptomatic support is needed to address the involuntary cough reflex. The drug's therapeutic use is commonly applied in the context of dry cough, which may include management of symptoms related to acute upper respiratory infection. This therapeutic utility is generally centered on symptoms of high-frequency, non-productive coughing that may interfere with a patient's comfort.

The medication is generally applied for the symptomatic relief of the dry, irritating cough associated with various respiratory tract irritations. The relevant conditions commonly used include acute bronchitis, upper respiratory tract infections (URTIs), and cough patterns accompanying chronic inflammatory airway syndromes.

The practical benefit focuses on managing cough that interferes with rest, and may assist in addressing symptoms related to sleep disruption and persistent throat irritation. The overall benefit is aligned with easing the patient’s discomfort, which may contribute to moderating the severity and frequency of irritating coughing spasms.

“The overall benefit is aligned with easing the patient’s discomfort, which may contribute to moderating the severity and frequency of irritating coughing spasms.”

Quick Fact: Managing Disruptive Cough Symptoms

Quick Fact: Managing Disruptive Cough Symptoms. The medicine is relevant when symptoms interfere with daily comfort and may assist with addressing symptoms associated with acute or chronic episodes of coughing.

Regulatory References

NIH ClinicalTrials.gov registry

Eligibility and Restrictions for Use

Official Population Eligibility Rules

The official regulatory profile for Broncatox (Levodropropizine) establishes clear eligibility rules based on age, physiological status, and underlying health conditions. Use is formally permitted for adults and children aged 2 years and above.

Use is contraindicated (absolutely prohibited) for several specific populations, as documented in the prescribing information. This includes all children under 2 years of age, women who are pregnant, planning to conceive, or breastfeeding, and individuals with known hypersensitivity to the active substance.

Contraindications related to underlying conditions include patients with severe hepatic disorders and those with respiratory issues characterized by excessive mucus discharge (bronchorrhea) or reduced mucociliary function (e.g., Kartagener syndrome).

Special caution is required for use in elderly patients and for individuals with severe renal insufficiency (creatinine clearance below 35 mL/min). The label also specifies caution for diabetic patients due to excipient content in some oral formulations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documentation for Broncatox (Levodropropizine) describes a narrow interaction profile primarily centered on pharmacodynamic potentiation of central nervous system (CNS) effects. No strict contraindicated medicinal product combinations or mandatory timing separation rules are listed in the official prescribing information.

Documented Interaction Patterns

Interaction Type	Interacting Substance/Class	Official Constraint
Pharmacodynamic Additive Effect	Sedative Drugs (e.g., Benzodiazepines)	Caution is required due to potential for enhanced sedation.
Substance Interaction	Alcohol (Ethanol)	May increase the risk of CNS adverse effects, such as drowsiness.
Absence of Pharmacokinetic Interaction	beta2-agonists, Methylxanthines, Antibiotics	No clinically significant pharmacokinetic interactions observed.

Co-administration with sedative medicinal products, including benzodiazepines, requires caution as the combination may result in an additive effect, potentially leading to enhanced drowsiness or somnolence. This concern for enhanced CNS depression also applies to the concurrent ingestion of alcohol.

Regulatory documentation also includes a specific caution for elderly patients, who are noted for their potential for increased sensitivity to the effects of various medicines, which may amplify the impact of the documented sedative interaction. The medicine has shown no evidence of interaction with common treatments for bronchopulmonary diseases, confirming the lack of pharmacokinetic interactions with classes such as beta2-agonists, methylxanthines, and antibiotics.

Mechanism of Action

How Broncatox Works: Mechanism of Action

Broncatox initiates its action by selectively binding to beta2-Adrenoceptors (beta2-ARs) on airway smooth muscle cells, functioning as an agonist. This interaction activates the associated Gs protein and subsequent Adenylyl Cyclase enzyme, triggering a rise in intracellular cyclic Adenosine Monophosphate (cAMP) levels.

Elevated cAMP activates Protein Kinase A (PKA), which interferes with the cell's contractile machinery by influencing intracellular calcium ion (Ca^2+) dynamics and myosin light chain phosphorylation. This molecular cascade leads directly to the relaxation of the airway smooth muscle, resulting in the key physiological change of bronchodilation and an increase in airflow.

In addition to muscle relaxation, the beta2-AR mechanism extends to local immune regulation. By stabilizing mast cells, the mechanism limits the release of certain pro-constrictive and inflammatory mediators, which complements the primary bronchodilating effect and results in diminished local inflammatory signaling within the respiratory tract.

Dosage and Administration Information

Broncatox (levodropropizine) is used in accordance with established administration protocols.

Administration and Dosing

Broncatox is an oral solution or syrup that must be measured using the provided dosing device.

Population	Single Dose	Maximum Frequency	Minimum Interval
Adults (12 years and older)	60 mg (e.g., 10 mL of 6 mg/mL syrup)	Up to three times daily	6 hours
Children (2 to 12 years)	1 mg/kg body weight	Up to three times daily	6 hours

Dosing for Children: For convenience, the dosage can be approximated by weight ranges (e.g., 10-20 kg approx 3 mL per dose; 20-30 kg approx 5 mL per dose).
Maximum Daily Dose (Adults): The total dose must not exceed 180 mg over a 24-hour period.
Children Under 2 Years: Use of this medicine is generally not recommended or is contraindicated.

Timing and Duration

Timing: The syrup should preferably be taken away from meals (on an empty stomach) due to the lack of complete data on the effect of food on its absorption.
Course Duration: The period of treatment should remain brief and must not exceed seven days. The medicine should be stopped as soon as the intended effect is achieved. If symptoms persist after seven days, administration must be discontinued, and a healthcare professional should be consulted.

Recent Clinical Evidence

Overview of Trial Outcomes

Overview of Outcomes

Studies have explored the use of the agent for mild to moderate symptoms of Condition A, and research examined whether the agent was associated with a reduction in symptoms over time. Findings from studies evaluated whether the agent was associated with a reduction in the severity of flare-ups experienced by participants.

Research has explored the timing of any observed change, with some studies noting changes within the first week of administration.

Data from three Phase 3 trials evaluated the agent in comparison to placebo. Research assessed the quality of life for participants. Some findings indicated that the agent was associated with changes in quality of life measures.

Findings on Specific Symptoms

Joint Pain

Studies evaluated the effect of the agent on joint pain and explored the timeline of any observed changes.

Swelling

Studies examined whether the agent was associated with a reduction in swelling.

Administration and Safety Findings

The agent was administered daily in the studies reviewed. Studies exploring absorption noted that the agent was administered with food in certain trials.

Reported side effects in the trials included those classified as mild in the study reports. Study participant criteria varied across research. Individuals with a history of liver issues were generally excluded from trials, and clinical suitability for any treatment is a matter for discussion with a healthcare provider.

Frequently Asked Questions (FAQ)

Common questions about Broncatox (FAQ)

Q: What are the most common side effects of Broncatox?

According to official product information, the majority of documented adverse reactions are categorized as very rare or of unknown frequency. The most frequently noted reactions involve the nervous system, such as somnolence (drowsiness), headache, or dizziness. Gastrointestinal issues, including nausea, vomiting, or indigestion, are also among the commonly reported effects.

Q: What type of cough is Broncatox used to treat and is it safe for a productive (wet/mucus) cough?

Broncatox is indicated only for the symptomatic relief of a non-productive, or dry, cough. Regulatory documents state that use is contraindicated (prohibited) for patients with conditions characterized by excessive bronchial mucus discharge or impaired ability to clear mucus (mucociliary function).

Q: Is it safe for me to drive or operate machinery while taking Broncatox?

Due to the potential for side effects like drowsiness (somnolence) and dizziness, the official product labeling notes that caution is necessary for tasks requiring mental alertness, such as driving or operating machinery. The use of alcohol or other sedating drugs may enhance these effects.

Q: How long does it take for Broncatox syrup to start working after I take a dose?

Studies of how the drug is absorbed, which are part of the regulatory profile, indicate that the active substance, levodropropizine, is rapidly absorbed. The maximum concentration of the medicine in the body is generally reached in under two hours after administration.

Q: Can I use Broncatox if I am currently pregnant or breastfeeding?

Official regulatory documents state that the use of Broncatox is absolutely contraindicated during both pregnancy and while breastfeeding. This is a mandatory restriction because there is insufficient safety data regarding its use in these specific populations.

How should Broncatox be stored and disposed of?

The official regulatory documents define mandatory conditions for the storage and disposal of Broncatox (levodropropizine oral solution/syrup).

Storage Conditions

Requirement	Official Labeled Condition
Temperature Limit	Store at a temperature not exceeding 30°C (86°F). Do not freeze.
Protection	Protect from light and store in a dry place.
Container Rule	Keep the medicine in the original container and ensure the container is tightly closed.
Stability	After first opening the bottle, the in-use shelf life is limited, typically to 1 month or 6 weeks, depending on the formulation.
Safety	Keep out of the sight and reach of children to prevent accidental ingestion.